Abbisko Cayman Ltd. Registered Shares DL -,00001
- BID
1.19
- ASK
1.2
- 1,681 Units1,667 Units
- 07/21, 10:43:13 AM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
1.74%
Market Cap
-
P/E Ratio
135.66
Dividend Yield
0.00 %
Earnings per Share
0.01 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 1.19 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 10:33:16 AM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 1.19 | 1.17 |
| PREV. DAY'S PRICE | 1.17 | (07/20) |
| CHANGE DAY BEFORE | +0.02 | 1.71 % |
| 52 WEEK HIGH / LOW | 2.12 (10/08) | 0.935 (06/10) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.09 | 0.01 | 0.01 | -0.04 | -0.02 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | 95.04 | 135.66 | - | - |
PRICE - BOOK RATIO | 1.16 | 1.50 | 4.08 | - | - |
PRICE - SALES RATIO | 112.17 | 5.47 | 12.54 | - | - |
PRICE - CASH FLOW RATIO | - | 66.73 | 57.32 | - | - |
Master Data
| WKN | A3C4Y0 |
| ISIN | KYG0028A1085 |
| SYMBOL | 8ZD |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | ABBISKO CAYMAN DL-,00001 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -3.31 % | 17.59 % | -18.18 % | -18.75 % | 1.74 % | 300.68 % | - | -15.83 % |
| HIGH | 1.25 | 1.29 | 1.52 | 1.53 | 2.12 | 2.12 | - | 1.60 |
| LOW | 1.12 | 0.98 | 0.94 | 0.94 | 0.94 | 0.25 | - | 0.94 |
Dividende
pro Aktie
ABBISKO CAYMAN DL-,00001 does not deliver dividend information
Company profile
Abbisko Cayman Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The firm designed and developed a pipeline of sixteen candidates focused on oncology, including six candidates at clinical stage. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company was founded by Yao Chang Xu, Hong Ping Yu, and Zhui Chen on April 12, 2016 and is headquartered in Shanghai, China.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.